Oral mTOR inhibitor tablets for advanced renal cell carcinoma, breast cancer, and neuroendocrine tumors. Acquired by procurement teams in cancer institutes from biotech suppliers for chronic therapy in patients monitored by multidisciplinary oncology teams.